Evidence map›Paper›PMID 36401335›Full record

ArticleArthritis research & therapy2022

Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative.

Xiuying Li, Angela Cesta, Mohammad Movahedi, Claire Bombardier

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Clinical and Sonographic Pattern of Late-Onset and Early-Onset Rheumatoid Arthritis: Comparative Study.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2026
    Article
  8. Article
  9. Article
  10. Late Onset Rheumatoid Arthritis.Aging and disease · 2025
    Review
  11. Review
  12. Article
  13. Age of onset of rheumatoid arthritis and radiographic changes.Seminars in arthritis and rheumatism · 2025
    Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiuying LiOntario Best Practices Research Initiative, Toronto General Hospital Research Institute, University Health Network, 200 Elizabeth Street, 13EN-224, Toronto, ON, M5G 2C4, Canada.
Angela CestaOntario Best Practices Research Initiative, Toronto General Hospital Research Institute, University Health Network, 200 Elizabeth Street, 13EN-224, Toronto, ON, M5G 2C4, Canada.
Mohammad MovahediOntario Best Practices Research Initiative, Toronto General Hospital Research Institute, University Health Network, 200 Elizabeth Street, 13EN-224, Toronto, ON, M5G 2C4, Canada.
Claire BombardierOntario Best Practices Research Initiative, Toronto General Hospital Research Institute, University Health Network, 200 Elizabeth Street, 13EN-224, Toronto, ON, M5G 2C4, Canada. claire.bombardier@utoronto.ca.ORCID 0000-0001-5083-2137

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prevalence of rheumatoid arthritis (RA) in persons 60 years or older is estimated to be 2%. Late-onset rheumatoid arthritis (LORA) is traditionally defined as the onset of RA after the age of 60 years. Compared to younger-onset rheumatoid arthritis (YORA) which occurs before the age of 60 years, LORA has unique characteristics and disease manifestations. To date, few reports have addressed LORA and the prognosis of LORA patients remains unclear. We compared the clinical characteristics, time to remission and treatment regimen at remission between LORA and YORA patients.

methodsThis prospective cohort study used a registry database in Ontario, Canada from 2008 to 2020. Patients were included if they had active rheumatoid arthritis (RA) disease (≥1 swollen joint) and were enrolled within 1 year of diagnosis. LORA was defined as a diagnosis of RA in persons 60 years and older and YORA as a diagnosis of RA in persons under the age of 60. Remission was defined by Disease Activity Score 28 (DAS28) ≤2.6. A multivariable Cox proportional hazards model was used to estimate time to remission.

resultsThe study included 354 LORA patients and 518 YORA patients. The mean (standard deviation) baseline DAS28 score was 5.0 (1.3) and 4.8 (1.2) in LORA and YORA patients, respectively (p=0.0946). Compared to YORA patients, the hazard ratio for remission in LORA patients was 1.10 (95% confidence interval 0.90 to 1.34 p=0.36) after adjusting for other prognostic factors. For patients who reached remission, LORA patients were less likely to be on a biologic or Janus kinase (JAK) inhibitor (16% vs. 27%) and more likely to be on a single conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD) (34% vs. 27%) than YORA patients (p=0.0039).

conclusionLORA and YORA patients had similar prognosis in terms of time to remission. At remission, LORA patients were more likely to be on a single csDMARD without a biologic or JAK inhibitor.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidBiological ProductsJanus Kinase InhibitorsAge of OnsetHumansMiddle AgedOntarioProspective StudiesSeverity of Illness IndexAntirheumatic AgentsBiological ProductsJanus Kinase InhibitorsLate onsetPrognosisRheumatoid arthritisTime to remissionTreatment regimen

Identifiers

PMID36401335
PMCPMC9675233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.